Men being treated with hormone therapy for prostate cancer are not always getting bone-strengthening drugs they may need according to a Canadian study reported in a research letter in JAMA. A potentially serious side effect of the androgen-deprivation therapy often prescribed to prostate cancer patients is an increased risk of bone loss and fracture. Several consensus guidelines recommend bisphosphonate therapy for men receiving hormones but the new study found that the bone strengthening treatment was underused even in men with osteoporosis.
